Cameron Miller-Patterson1, Jesse Y Hsu2, Lana M Chahine3, James F Morley4, Allison W Willis5. 1. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, 3900 Woodland Ave., Philadelphia, PA, 19104, USA. millerpatterson@gmail.com. 2. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Epidemiology and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
PURPOSE: To determine whether dysautonomia can stratify individuals with other prodromal markers of Parkinson's disease (PD) for risk of phenoconversion and functional decline, which may help identify subpopulations appropriate for experimental studies. METHODS: Data were obtained from Parkinson's Progression Markers Initiative. Cohorts without PD but with at-risk features were included (hyposmia and/or rapid-eye-movement-sleep behavior disorder, LRRK2 gene mutation, GBA gene mutation). Dysautonomia measures included Scales-for-Outcomes-in-Parkinson's-Disease Autonomic (SCOPA-AUT), seven SCOPA-AUT subscales, and cardiovascular dysfunction (supine hypertension, low pulse pressure, neurogenic orthostatic hypotension). Outcome measures were phenoconversion and Schwab-and-England Activities-of-Daily-Living (SE-ADL) ≤ 70, which indicates functional dependence. Cox proportional-hazards regression was used to evaluate survival to phenoconversion/SE-ADL ≤ 70 for each dysautonomia measure. If a significant association was identified, a likelihood-ratio test was employed to evaluate whether a significant interaction existed between the measure and cohort. If so, regression analysis was repeated stratified by cohort. RESULTS: Median follow-up was 30 months. On multivariable analysis, gastrointestinal and female sexual dysfunction subscales were associated with increased risk of phenoconversion, while the cardiovascular subscale and neurogenic orthostatic hypotension were associated with increased risk of SE-ADL ≤ 70; respective hazard ratios (95% confidence intervals) were 1.13 (1.01-1.27), 3.26 (1.39-7.61), 1.87 (1.16-2.99), 5.45 (1.40-21.25). Only the association between the cardiovascular subscale and SE-ADL ≤ 70 was modified by cohort. CONCLUSIONS: Symptoms of gastrointestinal and female sexual dysfunction predict phenoconversion in individuals with other risk markers for PD, while signs and symptoms of cardiovascular dysfunction may be associated with functional decline.
PURPOSE: To determine whether dysautonomia can stratify individuals with other prodromal markers of Parkinson's disease (PD) for risk of phenoconversion and functional decline, which may help identify subpopulations appropriate for experimental studies. METHODS: Data were obtained from Parkinson's Progression Markers Initiative. Cohorts without PD but with at-risk features were included (hyposmia and/or rapid-eye-movement-sleep behavior disorder, LRRK2 gene mutation, GBA gene mutation). Dysautonomia measures included Scales-for-Outcomes-in-Parkinson's-Disease Autonomic (SCOPA-AUT), seven SCOPA-AUT subscales, and cardiovascular dysfunction (supine hypertension, low pulse pressure, neurogenic orthostatic hypotension). Outcome measures were phenoconversion and Schwab-and-England Activities-of-Daily-Living (SE-ADL) ≤ 70, which indicates functional dependence. Cox proportional-hazards regression was used to evaluate survival to phenoconversion/SE-ADL ≤ 70 for each dysautonomia measure. If a significant association was identified, a likelihood-ratio test was employed to evaluate whether a significant interaction existed between the measure and cohort. If so, regression analysis was repeated stratified by cohort. RESULTS: Median follow-up was 30 months. On multivariable analysis, gastrointestinal and female sexual dysfunction subscales were associated with increased risk of phenoconversion, while the cardiovascular subscale and neurogenic orthostatic hypotension were associated with increased risk of SE-ADL ≤ 70; respective hazard ratios (95% confidence intervals) were 1.13 (1.01-1.27), 3.26 (1.39-7.61), 1.87 (1.16-2.99), 5.45 (1.40-21.25). Only the association between the cardiovascular subscale and SE-ADL ≤ 70 was modified by cohort. CONCLUSIONS: Symptoms of gastrointestinal and female sexual dysfunction predict phenoconversion in individuals with other risk markers for PD, while signs and symptoms of cardiovascular dysfunction may be associated with functional decline.
Authors: Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: Andrea Pilotto; Sebastian Heinzel; Ulrike Suenkel; Stefanie Lerche; Kathrin Brockmann; Benjamin Roeben; Eva Schaeffer; Isabel Wurster; Rezzak Yilmaz; Inga Liepelt-Scarfone; Anna-Katharina von Thaler; Florian G Metzger; Gerhard W Eschweiler; Ron B Postuma; Walter Maetzler; Daniela Berg Journal: Mov Disord Date: 2017-05-16 Impact factor: 10.338
Authors: Philipp Mahlknecht; Arno Gasperi; Atbin Djamshidian; Stefan Kiechl; Heike Stockner; Peter Willeit; Johann Willeit; Gregorio Rungger; Werner Poewe; Klaus Seppi Journal: Mov Disord Date: 2018-02-13 Impact factor: 10.338
Authors: Sebastian Heinzel; Daniela Berg; Thomas Gasser; Honglei Chen; Chun Yao; Ronald B Postuma Journal: Mov Disord Date: 2019-08-14 Impact factor: 10.338
Authors: Kristina Kulcsarova; Joaquim Ribeiro Ventosa; Eva Feketeova; Milan Maretta; Norbert Lesko; Miroslav Benca; Vladimir Han; Laura Gombosova; Janette Baloghova; Miriam Slavkovska; Maria Brosmanova; Zuzana Vancova; Jan Lepej; Miroslava Rabajdova; Lubos Ambro; Stefan Toth; Filip Kudela; Igor Kudela; Lujza Strigacova; Veronika Roskovicova; Zuzana Gdovinova; Matej Skorvanek Journal: Parkinsonism Relat Disord Date: 2021-04-30 Impact factor: 4.891
Authors: Kathrin Marini; Klaus Seppi; Lena Tschiderer; Stefan Kiechl; Heike Stockner; Peter Willeit; Johann Willeit; Atbin Djamshidian; Gregorio Rungger; Werner Poewe; Philipp Mahlknecht Journal: Mov Disord Date: 2021-03-17 Impact factor: 10.338